v3.26.1
Condensed Balance Sheets - USD ($)
Mar. 31, 2026
Dec. 31, 2025
Dec. 31, 2024
Liabilities, Current [Abstract]      
Accrued expenses $ 225 $ 659  
TOTAL LIABILITIES 37,928 659  
Commitments and Contingencies  
SHAREHOLDERS' DEFICIT      
Additional paid-in capital 10 10  
Accumulated deficit (37,928) (659)  
Total Stockholder's Deficit (37,928) (659)  
Archimedes Tech SPAC Partners II Co      
Current assets      
Cash 1,077,839 1,362,766  
Prepaid expenses 140,921 111,403  
Total current assets 1,218,760 1,474,169  
Deferred offering costs     $ 429,691
Prepaid insurance   9,896  
Demand deposit held in Trust Account 242,002,931 239,860,969 0
TOTAL ASSETS 243,221,691 241,345,034 429,691
Liabilities, Current [Abstract]      
Accrued expenses 305,087 61,277 23,000
Accrued offering costs   75,000 268,358
Due to related party 4,283 1,239 0
Total current liabilities   137,516 483,391
Deferred underwriting fee payable 8,050,000 8,050,000  
TOTAL LIABILITIES 8,359,370 8,187,516 483,391
Commitments and Contingencies
Ordinary shares subject to possible redemption, 23,000,000 shares at redemption value of $10.52 and $10.43 per share as of March 31, 2026 and December 31, 2025, respectively 242,002,931 239,860,969  
SHAREHOLDERS' DEFICIT      
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding
Ordinary shares, $0.0001 par value; 400,000,000 shares authorized; 6,590,000 shares issued and outstanding (excluding 23,000,000 shares subject to possible redemption) as of March 31, 2026 and December 31, 2025 659 659 575
Additional paid-in capital     24,425
Accumulated deficit (7,141,269) (6,704,110) (78,700)
Total Stockholder's Deficit (7,140,610) (6,703,451) (53,700)
TOTAL LIABILITIES AND STOCKHOLDER'S DEFICIT 243,221,691 241,345,034 [1] 429,691 [1]
Related Party [Member] | Archimedes Tech SPAC Partners II Co      
Liabilities, Current [Abstract]      
Due to related party $ 4,283 $ 1,239  
Promissory note - related party     $ 192,033
[1] As of December 31, 2024, included an aggregate of up to 750,000 ordinary shares that were subject to forfeiture depending on the extent to which the underwriters’ over-allotment option was exercised (see Note 5). On February 12, 2025, the Company consummated its Initial Public Offering and sold 23,000,000 Units, including 3,000,000 Units sold pursuant to the full exercise of the underwriters’ option to purchase additional units to cover the over-allotment; as a result, the 750,000 ordinary shares were no longer subject to forfeiture.